Banner

FDA Briefs - March 1, 2002

Article

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

May 10th 2021

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

May 10th 2021

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023

Dopavision completes enrollment in trial for the digital treatment of myopia

October 2nd 2023

ROP: Treating and preventing blindness in preterm babies

October 18th 2021

Orbis International, Siloam Vision unite to save sight of premature infants using artificial intelligence

September 25th 2023

Managing a changing landscape of IRD pediatric cases

May 10th 2021

COVID-19 treatment changes infant’s eye color

September 6th 2023

WIO 2023: Cross-linking in pediatric patients: The case for treating keratoconus without waiting for disease progression

August 25th 2023
© 2023 MJH Life Sciences

All rights reserved.